Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Periconceptional Exposure to Contraceptive Pills and Risk for Down Syndrome

Abstract

OBJECTIVE: There are some studies which analyzed the relationship between prenatal exposure to oral contraceptives (OCs) and Down syndrome, with conflicting results even in women using OCs and conceiving at different intervals after discontinuing the use of contraceptive pills. We analyzed the risk for Down syndrome in infants of women who become pregnant while taking OC.

STUDY DESIGN: We used the data from the Spanish Collaborative Study of Congenital Malformations (ECEMC). The ECEMC is a case–control study and surveillance system. For each malformed infant (case), the next non-malformed infant of the same sex born in the same hospital is selected as a control subject, from whom the collaborating physicians collected the same data as for the malformed infant. For the present study, we used two different approaches. First, the pair-matching analysis. Second, a case–control using the rest of the total of 17,183 controls from the ECEMC database with specified data on maternal use of OCs and maternal age. To control for maternal age, we used a logistic regression analysis.

RESULTS: The results show an increased risk of 2.8-fold for infants with Down syndrome in women younger than 35 years of age if the mother became pregnant while she was taking OCs. We did not observe this result for women older than 34 years of age.

CONCLUSION: Our results showed that the risk for Down syndrome in infants born to mothers with less than 35 years of age (as a group) who became pregnant while taking OCs is near the risk for Down syndrome of mothers with more than 34 years of age, women who are candidates for prenatal diagnosis. Thus, based on our results, one may consider the possibility of offering prenatal diagnosis for Down syndrome to young women who became pregnant while taking OCs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Ford JH Induction of chromosomal errors Lancet 1973 1 54

    Article  CAS  Google Scholar 

  2. Lejeune J, Prieur M Oral contraceptive and trisomy 21. A retrospective study of 730 cases Semin Hosp 1979 55 1985–90

    CAS  Google Scholar 

  3. Read SG The distribution of Down's syndrome J Ment Defic Res 1982 26 215–27

    PubMed  Google Scholar 

  4. Janerich DT, Flink EM, Keog MD Down's syndrome and oral contraceptive usage Br J Obstet Gynecol 1976 83 617–20

    Article  CAS  Google Scholar 

  5. Ericson A, Källén B, Lindsten J Lack of correlation between contraceptive pills and Down's syndrome Acta Obstet Gynecol Scand 1983 62 511–4

    Article  CAS  Google Scholar 

  6. Harlap S, Shiono PH, Ramcharan S, et al Chromosomal abnormalities in the Kaiser permanent birth defects study, with special reference to contraceptive use around the time of conception Teratology 1985 31 381–7

    Article  CAS  Google Scholar 

  7. Källén B Maternal use of oral contraceptives and Down syndrome Contraception 1989 39 503–6

    Article  Google Scholar 

  8. Mikkelsen M Epidemiology of trisomy 21: population, peri- and antenatal data Hum Genet 1981 (Suppl 2) 211–226 Cited by Yang Q, Sherman SL, Hassold TJ, et al. Risk factors for trisomy 21: maternal cigarette smoking and oral contraceptive use in a population-based case–control study. Genet Med 1999;1:80–8

  9. Harlap S, Eldor J Births following oral contraceptive failure Obstet Gynecol 1980 55 447–52

    CAS  PubMed  Google Scholar 

  10. Salvador J, Martínez-Frías ML Estudio epidemiológico del síndrome de Down en España Madrid: Ed Ministerio de Sanidad y Consumo 1989

    Google Scholar 

  11. Martínez-Frías ML, Bermejo E, Rodríguez-Pinilla E Diagnóstico clínico del síndrome de Down basado en 11 rasgos. Análisis epidemiológico de la especificidad de los rasgos estudiados An Esp Pediatr 1996 45 522–6

    PubMed  Google Scholar 

  12. Martínez-Frías ML, Frías JL, Rodríguez-Pinilla E, et al Value of clinical analysis in epidemiological research: the Spanish registry experience Am J Med Genet 1991 41 192–5

    Article  Google Scholar 

  13. Martínez-Frías ML Developmental field defects and associations: epidemiological evidence of their relationship Am J Med Genet 1994 49 45–51

    Article  Google Scholar 

  14. Martínez-Frías ML, Rodríguez-Pinilla E, Bermejo E, Prieto L Prenatal exposure to sex hormones: a case–control study Teratology 1998 57 8–12

    Article  Google Scholar 

  15. Janerich DT, Flink EM, Keogh MD Down's syndrome and oral contraceptive usage Br J Obstet Gynecol 1976 83 617–20

    Article  CAS  Google Scholar 

  16. Yang Q, Sherman SL, Hassold TJ, et al Risk factors for trisomy 21: maternal cigarette smoking and oral contraceptive use in a population-based case–control study Genet Med 1999 1 80–8

    Article  CAS  Google Scholar 

  17. Gaulden ME Maternal age effect: the enigma of Down syndrome and other trisomic conditions Mutat Res 1992 296 69–88

    Article  CAS  Google Scholar 

  18. Van Blerkom J, Antczak M, Schrader R The developmental potential of the human oocyte is related to the dissolved oxygen content of follicular fluid: association with vascular endothelial growth factor levels and perifollicular blood flow characteristics Hum Reprod 1997 12 1047–55

    Article  CAS  Google Scholar 

  19. Martínez-Frías ML Frecuencia al nacimiento de niños con síndrome de Down en España: análisis por años y por Comunidades Autónomas. Efecto del diagnóstico prenatal Prog Diagn Pren 1996 8 327–37

    Google Scholar 

  20. Martínez-Frías ML, Bermejo E Frecuencia basal de defectos congénitos en España y su evolución en el tiempo: utilidad y significado de las distintas cifras de frecuencia Med Clin 1999 113 459–62

    Google Scholar 

Download references

Acknowledgements

We thank all the physicians who collaborated with the ECEMC in collecting the data.

Author information

Authors and Affiliations

Authors

Additional information

This work was supported, in part, by a grant from Instituto de Salud Carlos III, Ministerio de Sanidad y Consumo of Spain, and, in part, by Fundacin 1000 para la investigacin sobre defectos congnitos of Spain.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martínez-Frías, ML., Bermejo, E., Rodríguez-Pinilla, E. et al. Periconceptional Exposure to Contraceptive Pills and Risk for Down Syndrome. J Perinatol 21, 288–292 (2001). https://doi.org/10.1038/sj.jp.7210538

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jp.7210538

This article is cited by

Search

Quick links